NCT02075541View on ClinicalTrials.gov

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients With Persistent Airflow Obstruction.

PHASE2CompletedINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

July 8, 2014

Primary Completion Date

April 19, 2017

Study Completion Date

April 19, 2017

Conditions
Respiratory Disorders
Interventions
BIOLOGICAL

NTHi-10-AS01E

Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.

DRUG

NaCl Placebo

Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.

Trial Locations (14)

SE-631 88

GSK Investigational Site, Eskilstuna

SE-413 45

GSK Investigational Site, Gothenburg

SE-703 62

GSK Investigational Site, Örebro

SA14 8QF

GSK Investigational Site, Llanelli

LE3 9QP

GSK Investigational Site, Leicester

ST4 6QG

GSK Investigational Site, Stoke-on-Trent

BD9 6RJ

GSK Investigational Site, Bradford

DD1 9SY

GSK Investigational Site, Dundee

EH16 4SA

GSK Investigational Site, Edinburgh

L9 7AL

GSK Investigational Site, Liverpool

BH15 2JB

GSK Investigational Site, Poole, Dorset

M6 8HD

GSK Investigational Site, Salford

SO16 6YD

GSK Investigational Site, Southampton

WV10 0QP

GSK Investigational Site, Wolverhampton

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02075541 - A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients With Persistent Airflow Obstruction. | Biotech Hunter | Biotech Hunter